When researchers looked at different areas within an individual rectal cancer sample, they found cases in which each area contained different genetic mutations.
The findings could have significant implications for treatment recommendations.
Researchers from the University of Michigan Comprehensive Cancer Center used next-generation sequencing techniques to sample the genetic landscape of different geographic areas from tissue samples taken from six patients with rectal cancer.
They found that different regions of a single tumour shared as much as 93 percent of genetic mutations and as little as 67 percent.
"Our paper shows that individual parts of a tumour are different. Some tumours have a lot of variation and some don't. This is the first time anyone has shown this in rectal cancer," says lead study author Karin Hardiman, M.D., Ph.D., assistant professor of surgery at the University of Michigan Medical School.
Genetic variation has been found in other types of cancer, including lung cancer, kidney cancer, and some types of leukaemia.
Rectal cancer often returns in the area where it was removed, making treatments such as chemotherapy and radiation crucial in addition to surgery.
Chemotherapy choices often are determined from the genetic make-up of the tumour.
"When medical oncologists make decisions about targeted chemotherapy, they typically base that off the results of a single biopsy. If they're testing only one biopsy, it may or may not reflect what's in the rest of the tumour," Hardiman says.
The study authors hypothesise that the differences within a tumour might make the cancer more likely to resist targeted therapies.
They are studying patient biopsy samples and mouse models to understand why there is variation within a tumour and why that variation is not present in all tumours.
Mouse models of rectal cancer will also allow the researchers to understand whether certain therapies or combinations of therapies can make a tumour more or less likely to respond.
Results of the study appear in Laboratory Investigation.
Reference
Ulintz, Kuick, Hovelson et al. Intra-tumor genetic heterogeneity in rectal cancer, Laboratory Investigation, 16th November 2015
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.